Diabetic Macular Edema

Fatih C. Gundogan¹, Umit Yolcu², Fahrettin Akay³, Abdullah Ilhan⁴, Gokhan Ozge⁵, Salih Uzun⁶

ABSTRACT

Diabetic macular edema (DME), one of the most prevalent causes of visual loss in industrialized countries, may be diagnosed at any stage of diabetic retinopathy. The diagnosis, treatment, and follow up of DME have become straightforward with recent developments in fundus imaging, such as optical coherence tomography. Laser photoagulation, intravitreal injections, and pars plana vitrectomy surgery are the current treatment modalities; however, the positive effects of currently available intravitreally injected agents are temporary. At this point, further treatment choices are needed for a permanent effect.

Sources of data selection: The articles published between 1985-2015 years on major databases were searched and most appropriate 40 papers were used to write this review article.

KEY WORDS: Diabetic macular edema, Optical coherence tomography, Fluorescein angiography, Ranibizumab, Bevacizumab, Triamcinolone acetonide, Pars plana vitrectomy.

doi: http://dx.doi.org/10.12669/pjms.322.8496

How to cite this:
Gundogan FC, Yolcu U, Akay F, Ilhan A, Ozge G, Uzun S. Diabetic Macular Edema. Pak J Med Sci. 2016;32(2):505-510.
doi: http://dx.doi.org/10.12669/pjms.322.8496

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Diabetic macular edema (DME), one of the major complications of diabetic retinopathy (DRP), is also one of the leading causes of visual impairment in the working-age population.¹ DME occurs in nearly 12% of patients with DRP and causes more than 10,000 new cases of blindness per year.² Duration and type of diabetes directly affect the prevalence rate of DME. Patients can develop DME in the first five years following diagnosis of type I diabetes. The prevalence rate gradually reaches up to 40% within 30 years.³ About 5% of patients with type II diabetes already have DME at the time of diagnosis. Duration of diabetes, proteinuria, gender, cardiovascular disease, high levels of HbA1c, and use of diuretics are defined as systemic risk factors.⁴ DME can occur at any stage of DRP.

PATHOGENESIS

The pathogenesis of DME has not been thoroughly defined because there are complex processes with various contributing factors. Chronic hyperglycemia, hypercholesterolemia, free oxygen radicals, advanced glycation end-products, and protein kinase C are involved in the pathologic process.⁵ The common characteristic is the increase in levels of vascular endothelial growth factor (VEGF), which is responsible for the disruption of the inner blood–retinal barrier (BRB).⁶ Disruption of the BRB leads to the accumulation of subretinal and intraretinal fluid, which in turn alters the
macular structure and function. Leukocyte chemotaxis to vascular endothelium is another element of BRB breakdown and vascular leakage. Leukocytes induce endothelial dysfunction and capillary non-perfusion in multiple ways, such as disruption of tight junctions and free oxygen radicals. DRP stimulates the expression of adhesion molecules that facilitate the adhesion capacity of inflammatory cells; this stimulation is thought to be mediated by VEGF. It also has been reported that VEGF is responsible for neuronal apoptosis. Elevated VEGF levels can cause vascular leakage and BRB breakdown, directly and indirectly, via various mechanisms. Nitric oxide is another critical mediator in the pathogenesis of DME. It uses the similar metabolic methods, such as the induction and retention of leukocytes, increased secretion of VEGF, and dysfunction in cellular junctions. As the primary factor of DRP, hyperglycemia causes tissue edema, perfusion insufficiency, vascular dilation-elongation, BRB breakdown, and neuronal apoptosis, and it certainly takes part in the pathogenesis of DME. The vitreous humor may also be a source of proinflammatory cells and cytokines. In addition, the presence of vitreoretinal interface pathologies, such as epimacular membranes, can apply tractional forces to the macula and aggravate DME. Hypoxia, ischemia, genetic factors, and inflammatory mediators may contribute to the pathogenesis of BRB damage and DME. In the course of DME, Muller glial cell and pericyte dysfunction can be involved.

The β-adrenergic system is known for its particular roles in angiogenesis and neuronal damage, even in ocular tissues. Hypoxia may lead to catecholaminergic discharge, and catecholamines induce VEGF and hypoxia-inducible factor-1α (HIF-1α) expression via β-adrenergic receptors, while β-blockers reduce their expression and vascular leakage. β-1 and β-3 adrenergic receptors are present in retinal endothelial cells. Stimulation of β-3 adrenergic receptors triggers proliferation and migration of retinal and choroidal endothelial cells. In short, the β-adrenergic system induces both the secretion of proangiogenic factors and endothelial cell responses to form new vessels. These data suggest that the β-adrenergic system might be involved in the DRP process.

Various studies have recently been performed to understand the emerging role of microRNAs in diabetes and cardiovascular diseases. MicroRNAs are short, single-stranded, non-coding RNA sequences that bind to complementary sequences of target mRNAs and act as post-transcriptional regulators. Their activity usually induces gene silencing and prevents protein production. They are involved in multiple physiological and pathological mechanisms, including angiogenesis, diabetes, and cardiovascular diseases. For instance, they take part in pancreatic β-cell differentiation, insulin secretion, and insulin sensitivity. It has been reported that microRNAs are involved in retinal and choroidal neovascularization via down regulation of VEGF. Although not enough studies have been conducted regarding the role of microRNAs in DRP to come to distinct conclusions, there is strong evidence of their contribution. Different microRNAs have been defined that affect endothelial cell proliferation, apoptosis, VEGF expression, or neuronal damage during the course of DME. MicroRNA agonists or antagonists may constitute alternative treatment options in the management of DRP and its major complication, DME.

DIAGNOSIS AND CLASSIFICATION

The first step in the diagnosis of DME is the contact lens-aided slit-lamp biomicroscopy of the posterior pole. Biomicroscopic examination reveals the presence and location of macular thickening, exudates, and cystoid changes (Fig.1). Fundus fluorescein angiography (FFA) may show the areas of retinal capillary leakage (Fig.2a), and optical coherence tomography (OCT) can show retinal section images. With the aid of OCT, qualitative and quantitative evaluations of structural changes in the macula have become prominent in the diagnosis (Fig.2b), treatment, and follow up of DME. DME can be associated with or without exudates and can appear as focal, diffuse, and ischemic subtypes. Focal macular edema is characterized by fluorescein leakage from certain capillary areas, and it may be surrounded by hard exudates (circinate exudates) that are yellow to white.
in color and contain lipoprotein remnants of plasma extravasation from microaneurysms. The diffuse form is the result of generalized capillary dysfunction and BRB disruption. Cystoid macular edema usually comes along with diffuse DME. Ischemic DME, which results from microvascular occlusions in any part of the macular area, is observed in FFA as hypofluorescent macular areas. Fig. 3 shows a fundoscopic view and FFA of a diabetic retinopathy patient with focal macular edema.

In the past, the term “clinically significant macular edema” (CSME) was used to define patients who needed to be treated. CSME was identified in the presence of any of the following three fundoscopic examination findings. (Fig. 4)

1. Retinal thickening at or within 500 µ or 1/3 the disc diameter of the fovea.
2. Hard exudates at or within 500 µ of the fovea, with adjacent retinal thickening.
3. Retinal thickening greater than one disc diameter (1500 µ) in size that is within one disc diameter from the fovea.

However, these criteria were mostly discarded due to the emergence of OCT-based diagnosis. OCT images are now used in the diagnosis, treatment, and follow up of DME.

**MANAGEMENT STRATEGIES**

To prevent the development and progression of DME, it is essential to maintain strict glycemic control, reduce blood lipid levels, and regulate systemic blood pressure. The American Diabetes Association recommends that HbA1c levels must be kept under 7%, blood pressure under 130/80 mmHg, and total lipids under 100 mg/dL. Ocular treatments include retinal laser photoacoagulation, intravitreal administration of certain agents, and vitreoretinal surgery when necessary.

**Laser Treatment:** Laser treatment strategies have been derived mainly from the Early Treatment Diabetic Retinopathy Study (ETDRS), a randomized, prospective clinical trial that evaluated photoacoagulation in patients with diabetes in the USA. The ETDRS revealed that cases of CSME treated by laser photoacoagulation showed improved visual acuity, reduced risk of visual loss, and negligible visual field loss. Eyes without CSME did not benefit from laser photoacoagulation. Some recently published studies still emphasize the superiority of laser photoacoagulation compared to other options. Therefore, it is accepted as the current standard treatment for DME by many authors.

Some complications associated with laser photoacoagulation have been reported, such as
macular hemorrhage, choroidal neovascularization, decline in visual acuity and contrast sensitivity, and visual field defects. The aim of laser photocoagulation is to destroy the outer segments of photoreceptors and diminish oxygen consumption; in order to minimize this effect, several attempts have been made to optimize the parameters and application techniques.

**Anti-VEGF Agents:** Since the approval of bevacizumab for colorectal cancer in 2004 and ranibizumab for age-related macular degeneration in 2006, the number of ophthalmology fields in which anti-VEGF agents are used has been increasing. Pegaptanib, bevacizumab, ranibizumab, aflibercept, and KH902 are the agents currently used for retinal pathologies. Each agent has been the subject of several studies and has improved DME considerably. Currently, ranibizumab is the only agent approved by the US Food and Drug Administration for DME. Aflibercept, known as a “VEGF trap” because of its ability to deactivate all six VEGF proteins, is approved for use in wet age-related macular degeneration, but not yet in DME. Recent studies have reported better visual and anatomical results using aflibercept than using standard laser treatments, so it seems to be a promising agent.

Ranibizumab, a humanized monoclonal antibody fragment obtained from a mouse monoclonal anti-VEGF antibody, can interfere with all metabolic activities of VEGF. It has also proved to be effective in reducing macular thickness (Fig.5). A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study (the RESTORE study) was carried out to demonstrate the effects of ranibizumab, laser, and a combination of the two. The study showed that ranibizumab monotherapy and a combination of ranibizumab with laser therapy were more advantageous than laser treatment alone in terms of macular thickness and visual acuity gain. In addition, ranibizumab was well tolerated and did not pose any safety concerns during a three-year follow up.

Anti-VEGF agents are also used in relapsed DME cases. Gulkilik et al. reported the effectiveness of bevacizumab in cases with recurrent DME after pan retinal photocoagulation. Yuksel et al. reported that intravitreal bevacizumab treatment is effective in cases unresponsive to focal laser photocoagulation or and subtenon or intravitreal steroid injection. In some patients, response to intravitreal ranibizumab or bevacizumab may be incomplete or absent. It has been shown that switching to aflibercept provides anatomical and visual improvement in these cases due to the differences in pharmacodynamics of the drugs.

**Intravitreal Corticosteroids:** The benefits of glucocorticoids depend on their anti-inflammatory and anti-VEGF effects. Triamcinolone acetonide (TA) has been used for various ocular inflammatory disorders, including DME; several studies have considerable improvements in DME with TA alone or combined with anti-VEGF agents. Zhang et al. and Qi et al. reported significant visual improvements and decreased central macular thickness, particularly in the early post-injection period. However, the sustainable effects of TA are controversial, especially in terms of anatomical results. Elevated intraocular pressure (IOP) and cataract formation are the main complications of TA injection. While increased IOP sometimes requires medical treatment, only 2% of treated eyes in a previous study needed surgical intervention to reduce IOP. Fluocinolone acetonide and dexamethasone implants are new options found to be efficient in various studies.

**Pars Plana Vitrectomy:** Clinical trials have shown that performing pars plana vitrectomy (PPV) in selected DME cases reduced macular edema. PPV removes traction forces and proinflammatory substances and increases the oxygenation of inner retinal layers. The procedure can be performed when DME is resistant to laser treatment and anti-VEGF injections. It reduces macular thickness and provides visual acuity gain, and the effects are
mostly sustainable.48 Better surgical outcomes have been achieved by combining medical and surgical interventions.49 The presence of hard exudates, vitreous hemorrhage, and vitreomacular traction may be considered as indications for PPV in DME cases.46

CONCLUSION

DME is a serious public health problem that remains the leading cause of visual impairment in the industrialized world, despite innovations in its diagnosis and treatment. Medical difficulties and excessive economic burdens have forced scientists to seek new options for its treatment. While the discovery of the roles of VEGF and BRB breakdown in DME pathogenesis has accelerated therapeutic research, there are still many challenging cases that are refractory to all treatment efforts.

Declaration of interest: None of the authors have any conflict of interest with the submission.

Financial statement: The authors of this study did not receive any financial support for this submission.

REFERENCES

1. Klein R, Knudston MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859-1868. doi: 10.1016/j.j.phot.2008.08.023

2. Paulus YM, Gariano RF. Diabetic retinopathy: A growing concern in an aging population. Geriatrics. 2009;64(2):16-20.

3. Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27. doi: 10.1186/2045-3701-4-27

4. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59(5):1244-1253. doi: 10.2337/db09-1216

5. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32. doi: 10.1016/j.survophthal.2008.10.001

6. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes. 2008;57(4):1026-1033. doi: 10.2337/db07-0982

7. Leaf EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrosio AF, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48(11):5257-5265. doi: 10.1167/iovs.07-0112

8. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996;2(9):992-997.

9. Park HY, Kim JH, Park CK. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am J Pathol. 2014;184(6):1752-1762. doi: 10.1016/j.ajpath.2014.02.016

10. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73-79. doi: 10.1016/j.ophtha.2008.09.037

11. Santulli G, Lombardi A, Sorrentino D, Anastasio A, Del Giudice C, Formisano P, et al. Age-related impairment in insulin release: The essential role of beta(2)-adrenergic receptor. Diabetes. 2012;61(3):692-701. doi: 10.2337/db11-1027

12. Yang J, Liu Y, Fan X, Li Z, Cheng Y. A pathway and network review on beta-adrenergocceptor signaling and beta blockers in cardiac remodeling. Heart Fail Rev. 2014;19(6):799-814. doi: 10.1007/s10741-013-9417-4

13. Williams KP, Steindl J. Maintenance of beta-adrenergocceptor signaling can reduce Fas signaling in human retinal endothelial cells. Exp Eye Res. 2009;89(4):448-455. doi: 10.1016/j.exer.2009.04.015

14. Iacarrino G, Ciccarelli M, Sorrentino D, Galasso G, Campanile A, Santulli G, et al. Ischemic neangiogenesis enhanced by beta2-adrenergic receptor overexpression: A novel role for the endothelial adrenergocentric system. Circ Res. 2005;97(11):1182-1199. doi: 10.1161/01.RES.0000191541.06788.bb

15. Zhou J, Meng Y, Tian S, Chen J, Liu M, Zhuo M, et al. Comparative MicroRNA Expression Profiles of Cynomolgus Monkeys, Rat, and Human Reveal that miR-182 Is Involved in T2D Pathogenic Processes. J Diabetes Res. 2014;2014:760397. doi: 10.1155/2014/760397

16. Wronska A, Kurkowska-Jastrzebska I, Santulli G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol (Oxf). 2015;213(1):60-83. doi: 10.1111/apha.12416

17. Mastropasqua R, Toto L, Cipollone F, Santovito D, Carpineto P, Mastropasqua L. Role of microRNAs in the modulation of diabetic retinopathy. Prog Retin Eye Res. 2014;43:92-107. doi: 10.1016/j.preteyeres.2014.07.003

18. Shen J, Yang X, Xie B, Chen Y, Swaim M, Hackett SF, et al. MicroRNAs regulate ocular neovascularization. Mol Ther. 2008;16(7):1208-1216. doi: 10.1038/mt.2008.104

19. Bandello F, Pogruz R, Politio A, Pirraccchio A, Menchini F, Ambesi M. Diabetic macular edema: classification, medical and laser therapy. Semin Ophthalmol. 2005;18(4):251-258. doi: 10.1080/08820530390895262

20. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94(7):761-774.

21. Kiire CA, Porta M, Chong V. Medical management for diabetic macular edema. Arch Ophthalmol. 2008;126(5):692-701. doi: 10.1001/archophthalmol.2008.610

22. photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-1806.

23. Diabetic Retinopathy Clinical Research N, Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127(3):245-251. doi: 10.1001/archophthalmol.2008.610
24. Yun SH, Adelman RA. Recent developments in laser treatment of diabetic retinopathy. Middle East Afr J Ophthalmol. 2015;22(2):157-163.

25. Romero-Aroca P, Reyes-Torres J, Baget-Bernaldez M, Blasco-Sune C. Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev. 2014;10(2):100-112.

26. Okamoto M, Matsuura T, Ogata N. Effects of Panretinal Photocoagulation on Choroidal Thickness and Choroidal Blood Flow in Patients with Severe Nonproliferative Diabetic Retinopathy. Retina. 2015 Oct 7. [Epub ahead of print] doi: 10.1097/IAE.0000000000000800

27. Gardner TW. Complications of retinal laser therapy and their prevention. Semin Ophthalmol. 1991;6(1):19-26.

28. Dorin G. Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it? Semin Ophthalmol. 2004;19(1-2):62-68. doi: 10.1080/08820530390884173

29. Gonzalez VH, Giliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol. 2009;93(11):1474-1478.

30. Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, et al. Comparison of Afibbercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extraploration of Data to Clinical Practice. JAMA Ophthalmol. 2015;1-6.

31. Su L, Ren X, Wei H, Zhao L, Zhang X, Liu J, et al. Intravitreal Combination (KH902) for Surgical Treatment of Severe Proliferative Diabetic Retinopathy. Retina. 2015 Oct 7. [Epub ahead of print] doi: 10.1097/IAE.0000000000000900

32. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254.

33. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801. doi: 10.1016/j. ophtha.2011.12.039

34. Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Landzaert P, Massin P, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045-1053. doi: 10.1016/j. ophtha.2013.11.041

35. Gulkilik G, Taskapili M, Kocabora S, Muftuoglu G, Demirci G. Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy. Int Ophthalmol. 2010;30(6):697-702.

36. Yuksel E, Ozdek S, Yuksel N, Hasanreisoglu B. Intravitreal bevacizumab treatment for refractory diabetic macular edema. Int Ophthalmol. 2013;33(6):659-663.

37. Wood EH, Karth PA, Moshfeghi DM, Leng T. Short-Term Outcomes of Afibbercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2015;46(6):950-954.

38. Liu Q, Hu Y, Yu H, Yuan L, Hu J, Aitk A, et al. Comparison of Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab as the Primary Treatment of Clinically Significant Macular Edema. Retina. 2015;35(2):272-279.

39. Durukan AH, Memisoglu S, Gundogan FC. Is multifocal ERG a reliable index of macular function after triamcinolone acetonide injection in diffuse diabetic macular edema? Euro J Ophthalmol. 2009;19(6):1017-1027.

40. Zhang Y, Ma J, Meng N, Li H, Qu Y. Comparison of intravitreal triamcinolone acetonide with intravitreal bevacizumab for treatment of diabetic macular edema: A meta-analysis. Curr Eye Res. 2013;38(5):578-587. doi: 10.3109/02713683.2013.767351

41. Yolcu U, Sobaci G. The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections. Int Ophthalmol. 2015;35(1):73-79. doi: 10.1007/s10792-014-0019-5

42. Qi HP, Bi S, Wei SQ, Cui H, Zhao JB. Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis. Curr Eye Res. 2012;37(12):1136-1147. doi: 10.3109/0773788X.2012.705412

43. Bartesseli G, Amini P, Ezon IC, Nezgoda JT, Cheng L, Freeman WR. Impact on Intraocular Pressure after 20-Mg Decanted Triamcinolone Acetonide (Kenalog) Injection When Using Prophylactic Antiglaucoma Therapy. Retina. 2015;35(1):75-81.

44. Cabrera M, Yeh S, Albini TA. Sustained-release corticosteroid options. J Ophthalmol. 2014;2014:164692. doi: 10.1155/2014/164692

45. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema: The BEVORDEX Study. Ophthalmology. 2014;121(12):2473-2481.

46. Naverrete-Sanchis J, Zacco-Bosquets J, Tomas-Torrent JM, Diago T, Ortega-Evangelio L. Long-term effectiveness of vitrectomy in diabetic cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2015;253(5):713-719.

47. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci. 2014;55(2):617-24.

48. Golan S, Loewenstein A. Surgical treatment for macular edema. Semin Ophthalmol. 2014;29(4):242-256. doi: 10.1007/s10792-014-0013-0

49. Kolarov D, Just A, Wirbelauer C. Surgical treatment of chronic macular oedema with a combination therapy. Klin Monbl Augenheilkd. 2014;231(1):61-65. doi: 10.1055/s-0033-1360140

Author’s contributions:

**FCG:** Substantial contributions to conception and design, revising it critically for important intellectual content, final approval of the manuscript.

**UY:** Acquisition of data, drafting and final approval of the manuscript.

**FA and AI:** Substantial contributions to conception and design, drafting and final approval of the manuscript.

**GO and SU:** Acquisition of data, revising it critically for important intellectual content, final approval of the manuscript.